9 Results
April/May 2008
- Identity of Assay Interfering Substances
Michel Awwad, Ph.D., D. Wensel, P. Szklut Wyeth Pharmaceuticals
- Maximising Applications of Gene Expression Profiles Across a Multitude of Therapeutic Areas
Stewart Bates Director of Core Technologies, Discovery Technology Group GlaxoSmithKline
- From Biological Measures to Valid Biomarker: Predicting Success of Novel Therapeutic
Ole E. Vesterqvist, PhD, C. Hyung Park, PhD, J. Lynn Rutkowski, PhD Wyeth Research
- Building Target-Related Assays for Effective High- Content Analysis in Preclinical Drug Research
Philip Denner & Stefan Prechtl* Bayer Schering Pharma AG, LDB Screening, High-Content Analysis
- Short Hairpin RNAi and the Drug Discovery Process
Mark Edbrooke, Gene Modulation, Discovery Technology Group GlaxoSmithKline R&D
- Toys or Tools? – Automation in the Drug Discovery Process
Dalin Nie, Ph.D. Head of Compound Management & Automation AstraZeneca
- Assay Sciences: A Model for Improving Efficiency Through Centralization
Jonathan Wingfield, Ph.D., Team Leader, Darren Jones, Senior Scientist, Roger Clark, Senior Scientist, Peter Simpson, Ph.D., Associate Director of Assay Sciences AstraZeneca
- Predicting Drug Efficacy: Molecular Profiling Applications in Drug Development
Michael E. Burczynski, Clinical Translational Medicine and Christina M. Coughlin, Discovery Translational Medicine Wyeth Research
- Stem Cells and Aging: A Conversation with William Haseltine
Eve Herold Director of Public Policy Research and Education Genetics Policy Institute